Human Papillomavirus Protein E6 (E6) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Human Papillomavirus Protein E6 (E6) – Pipeline Review, H2 2016’, provides in depth analysis on Human Papillomavirus Protein E6 (E6) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papillomavirus Protein E6 (E6), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)

The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BioNTech AG

Cancer Research Technology Limited

Etubics Corporation

Genexine, Inc.

Inovio Pharmaceuticals, Inc.

MedImmune, LLC

Selecta Biosciences, Inc.

Tomegavax, Inc.

Transgene SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Human Papillomavirus Protein E6 (E6) Overview 7

Therapeutics Development 8

Human Papillomavirus Protein E6 (E6) - Products under Development by Stage of Development 8

Human Papillomavirus Protein E6 (E6) - Products under Development by Therapy Area 9

Human Papillomavirus Protein E6 (E6) - Products under Development by Indication 10

Human Papillomavirus Protein E6 (E6) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Human Papillomavirus Protein E6 (E6) - Products under Development by Companies 13

Human Papillomavirus Protein E6 (E6) - Products under Development by Universities/Institutes 15

Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development 22

BioNTech AG 22

Cancer Research Technology Limited 23

Etubics Corporation 24

Genexine, Inc. 25

Inovio Pharmaceuticals, Inc. 26

MedImmune, LLC 27

Selecta Biosciences, Inc. 28

Tomegavax, Inc. 29

Transgene SA 30

Human Papillomavirus Protein E6 (E6) - Drug Profiles 31

Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ETBX-041 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

GX-188E - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

human papillomavirus [serotypes 16] vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

human papillomavirus vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

INO-3106 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

INO-3112 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PVX-01 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SEL-701 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

TA-CIN - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

TG-4001 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

VGX-3100 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Vvax-001 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Human Papillomavirus Protein E6 (E6) - Dormant Projects 51

Human Papillomavirus Protein E6 (E6) - Discontinued Products 52

Human Papillomavirus Protein E6 (E6) - Featured News & Press Releases 53

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress 53

Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 53

Nov 05, 2015: Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer 54

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 55

Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial 56

Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress 57

Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients 58

Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology 59

Oct 30, 2014: Genexine’s HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial 59

Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 60

Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 60

Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 61

Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV 62

Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head & Neck Cancer 63

Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by BioNTech AG, H2 2016 22

Pipeline by Cancer Research Technology Limited, H2 2016 23

Pipeline by Etubics Corporation, H2 2016 24

Pipeline by Genexine, Inc., H2 2016 25

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 26

Pipeline by MedImmune, LLC, H2 2016 27

Pipeline by Selecta Biosciences, Inc., H2 2016 28

Pipeline by Tomegavax, Inc., H2 2016 29

Pipeline by Transgene SA, H2 2016 30

Dormant Projects, H2 2016 51

Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports